Ranolazine-d5

• Description:

  Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) [1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

• Product Name Alternative:

  CVT 303-d5; RS 43285-003-d5

• UNSPSC:

  12352005

• Target:

  Calcium Channel; Isotope-Labeled Compounds; Sodium Channel

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling; Others

• Field of Research:

  Cardiovascular Disease; Cancer

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(C=CC=C1C)=C1NC(CN(CC2)CCN2C([2H])([2H])C(O)([2H])C([2H])([2H])OC3=C(C=CC=C3)OC)=O

• Molecular Formula:

  C24H28D5N3O4

• Molecular Weight:

  432.57

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73 (1) :55-73.|[3]Wang WQ, et al. Antitorsadogenic effects of ({+/-}) -N- (2,6-dimethyl-phenyl) - (4[2-hydroxy-3- (2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325 (3) :875-81.|[4]Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418 (1-2) :105-10.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1092804-87-9]